Our Portfolio
Real results from research, collaboration and commercialisation.
Research with reach. Ventures with impact.
Innovation Ulster Limited turns Ulster University research and ideas into commercial ventures. Its portfolio spans health technologies, new therapies, software and creative industries, backing innovations as they move towards real-world use.
From Ulster research to FDA-granted devices
Neurovalens has received FDA De Novo grants for two non-invasive neurostimulation devices: Modius Lean, for weight management, and Modius Spero, for symptoms associated with PTSD. The pivotal US study of Modius Spero included 383 adults; the company reports that two-thirds of participants using the device experienced a clinically meaningful improvement in symptoms.
Personalised 3D planning for surgery
Axial3D turns medical scans into patient-specific digital and 3D-printed models that can support treatment planning. Its Axial3D Insight software has FDA 510(k) clearance for specified diagnostic and treatment-planning uses. Ulster’s published REF 2021 impact case study reported an average 62 minutes saved per procedure using the technology, rising to more than 3.5 hours in complex cases.
£1.5 million backing for Dia Beta Labs
In 2025, Ulster University spin-out Dia Beta Labs secured £1.5 million in public and private funding, supported by Invest NI’s Co-Fund III. The company is developing innovative peptides to treat metabolic diseases, with funding supporting progress towards first-in-human evaluation.
£1.5 million backing for StimOxyGen
In 2025, Ulster University spin-out StimOxyGen secured £1.5 million in public and private funding, supported by Invest NI’s Co-Fund III. The company is developing oxygen-generating nanoparticles designed to address tumour hypoxia, with funding supporting progress towards first-in-human evaluation.
Drug delivery designed for RNA medicines
SiSaf’s Bio-Courier platform uses bioabsorbable silicon to help stabilise and deliver biological medicines. A licensed formulation using the platform reached full enrolment in a randomised, placebo-controlled Phase II trial involving 158 people with alopecia areata.
Digital humans for global entertainment
HUMAIN applies Ulster research in realistic digital characters to film, television and video games. Ulster’s REF 2021 impact case study reported £1.15 million in contracts across 48 projects and 16 international partners, including Microsoft, Google, Activision, Warner and HBO. The case study also cited HUMAIN’s work on Call of Duty: Black Ops Cold War, Halo and Magic: The Gathering trailers.
Biosecurity technology for food production
ILIMEX raised £600,000 in equity finance in November 2025, including investment from IUL, to validate its Flufence air-sterilisation technology and expand into poultry and medicinal-mushroom production. The system combines airborne-pathogen detection with UVC treatment.
Recognition for a new melanoma approach
Klas Therapeutics, which is developing photodynamic therapy for melanoma, won the Northern Ireland regional “Best Early Stage” category in InterTradeIreland’s 2024 Seedcorn competition. It advanced to the all-island final.
A track record that includes an international acquisition
IUL also backed Intelesens, an Ulster medical-technology spin-out that developed wearable vital-signs monitors. US company UltraLinq acquired Intelesens in 2017, an example of Ulster University developed technology reaching an international buyer.
Our Portfolio Companies
Discover Innovation Ulster’s portfolio of spinout and startup companies, turning pioneering research, innovative ideas and expertise into successful businesses.
- Actionsense
- Axial 3D
- Axis Composites
- Datactics
- Dia Beta Labs Ltd
- Efectis UK - JV
- eXRT
- BDIC MedTech
- HARU - Responsible Ltd
- Humain
- Ilimex
- Inclutech
- Jenarron Therapeutics
- Klas Therapeutics
- Modern Nature
- Neuroconcise
- Neurovalens
- Performa Sports
- Pneuma Healthcare
- Pulse AI
- Respiratory Analytics
- Retinize
- SISAF Limited
- SonoTarg
- Stimoxygen Ltd
- Surecert
- SWIPS
